HM-61233

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameHM-61233

Drug Alias NameEGFR/ErbB-2 dual inhibitor (Hanmi)HM-60390 series (Hanmi)HM-60390HM-61233HM-60781

ClassificationSmall molecules

Mechanisms of ActionAnticancer protein kinase inhibitorsEpidermal growth factor receptor erbB1 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesHanmi Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHanmi Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A